Showing 39,921 - 39,940 results of 63,782 for search '(( 09 ((0 decrease) OR (a decrease)) ) OR ( 20 ((mean decrease) OR (we decrease)) ))', query time: 1.24s Refine Results
  1. 39921
  2. 39922
  3. 39923

    Changes in cardiac output with hemodialysis relate to net volume balance and to inferior vena cava ultrasound collapsibility in critically ill patients by Matthew J. Kaptein (8445279)

    Published 2021
    “…Net volume changes between cardiac outputs were estimated from “isonatremic volume equivalent” (0.9% saline) gains and losses.</p> <p>Cardiac output increased >10% in 15 of 42 encounters with IVC CI <20% after net volume removal, and in 1 of 16 encounters with IVC CI ≥20% after net volume administration (<i>p</i> = 0.0136). …”
  4. 39924

    Video_1_Thoracoscopic Trans-mitral Septal Myectomy for Hypertrophic Obstructive Cardiomyopathy in the Elderly.MP4 by Peijian Wei (12214859)

    Published 2022
    “…</p>Results<p>There were 46 and 20 patients in the younger and elderly groups, respectively. …”
  5. 39925
  6. 39926

    Effects of BMAL activator level on circadian oscillations in a stochastic model of isolated cellular oscillators. by Caroline H. Ko (240081)

    Published 2010
    “…These results show that as the percentage of total BMAL decreases, the mean period length decreases, along with an increase in the variance of the period. …”
  7. 39927
  8. 39928
  9. 39929
  10. 39930
  11. 39931

    Supplementary file 1_Spatiotemporal monitoring in beidagang wetland using Landsat time-series images and Google Earth Engine during 2000–2022.docx by Xinyue Zhang (271120)

    Published 2025
    “…Interannual dynamics during 2000–2022 revealed two distinct periods: terrestrial vegetation (TerV) dominance with permanent water (PW) below 10% (2000–2014), and PW exceeding 20% while temporary vegetation (TemV) decreased (2015–2022). …”
  12. 39932

    Effects of lixisenatide versus liraglutide (short- and long-acting GLP-1 receptor agonists) on esophageal and gastric function in patients with type 2 diabetes by Daniel R. Quast (8980434)

    Published 2020
    “…No significant changes from baseline in other parameters of esophageal motility and lower esophageal sphincter function were observed. Gastric acidity decreased significantly by -20.7 (-40.6, -0.8) % (p = 0.042) with the GLP-1 RAs.…”
  13. 39933

    MicroRNA-138 improves LPS-induced trophoblast dysfunction through targeting RELA and NF-κB signaling by Ailan Yin (10110696)

    Published 2021
    “…Although NF-κB and proinflammatory cytokines have been reported to be related to trophoblast dysfunction, the underlying mechanism remains unclear. Herein, we demonstrated the miR-138/RELA axis modulating the migratory ability, and invasive ability of HTR-8/SVneo and JEG-3 cells, as well as the inflammatory factor levels in response to LPS stimulation. miR-138 expression was upregulated in preeclampsia placenta and LPS-stimulated HTR-8/SVneo and JEG-3 cell lines. miR-138 overexpression rescued the migratory and invasive ability of HTR-8/SVneo and JEG-3 cells inhibited by LPS stimulation, and decreased LPS-induced TNF-α and IL-6 levels. …”
  14. 39934
  15. 39935

    Analysis of egress, invasion, and motility in parental and mutant lines. by Shaojun Long (4007162)

    Published 2017
    “…<i>0001</i>, significant for the time points of 2, 5, 10 and 15 min, but not significant for 0 and 20 min. Scale bar, 5 μM. <b>B</b>. Quantitative analysis of invasion by parasites grown for 2 days ± IAA (500 μM vs 0.1% ethanol) and used to challenge fresh HFF monolayers on coverslips for 20 min. …”
  16. 39936

    Image1_Novel multitarget analgesic candidate SZV-1287 demonstrates potential disease-modifying effects in the monoiodoacetate-induced osteoarthritis mouse model.TIF by Ádám István Horváth (15443678)

    Published 2024
    “…Introduction<p>Monoiodoacetate (MIA)-induced osteoarthritis (OA) is the most commonly used rodent model for testing anti-OA drug candidates. Herein, we investigated the effects of our patented multitarget drug candidate SZV-1287 (3-(4,5-diphenyl-1,3-oxazol-2-yl) propanal oxime) that is currently under clinical development for neuropathic pain and characterized the mouse model through complex functional, in vivo imaging, and morphological techniques.…”
  17. 39937

    Table1_Novel multitarget analgesic candidate SZV-1287 demonstrates potential disease-modifying effects in the monoiodoacetate-induced osteoarthritis mouse model.docx by Ádám István Horváth (15443678)

    Published 2024
    “…Introduction<p>Monoiodoacetate (MIA)-induced osteoarthritis (OA) is the most commonly used rodent model for testing anti-OA drug candidates. Herein, we investigated the effects of our patented multitarget drug candidate SZV-1287 (3-(4,5-diphenyl-1,3-oxazol-2-yl) propanal oxime) that is currently under clinical development for neuropathic pain and characterized the mouse model through complex functional, in vivo imaging, and morphological techniques.…”
  18. 39938

    Image3_Novel multitarget analgesic candidate SZV-1287 demonstrates potential disease-modifying effects in the monoiodoacetate-induced osteoarthritis mouse model.TIF by Ádám István Horváth (15443678)

    Published 2024
    “…Introduction<p>Monoiodoacetate (MIA)-induced osteoarthritis (OA) is the most commonly used rodent model for testing anti-OA drug candidates. Herein, we investigated the effects of our patented multitarget drug candidate SZV-1287 (3-(4,5-diphenyl-1,3-oxazol-2-yl) propanal oxime) that is currently under clinical development for neuropathic pain and characterized the mouse model through complex functional, in vivo imaging, and morphological techniques.…”
  19. 39939

    Image2_Novel multitarget analgesic candidate SZV-1287 demonstrates potential disease-modifying effects in the monoiodoacetate-induced osteoarthritis mouse model.TIF by Ádám István Horváth (15443678)

    Published 2024
    “…Introduction<p>Monoiodoacetate (MIA)-induced osteoarthritis (OA) is the most commonly used rodent model for testing anti-OA drug candidates. Herein, we investigated the effects of our patented multitarget drug candidate SZV-1287 (3-(4,5-diphenyl-1,3-oxazol-2-yl) propanal oxime) that is currently under clinical development for neuropathic pain and characterized the mouse model through complex functional, in vivo imaging, and morphological techniques.…”
  20. 39940

    A Pilot Randomized, Placebo Controlled, Double Blind Phase I Trial of the Novel SIRT1 Activator SRT2104 in Elderly Volunteers by Vincenzo Libri (48937)

    Published 2012
    “…Pharmacokinetic exposure increased less than dose-proportionally. Mean Tmax was 2–4 hours with elimination half-life of 15–20 hours. …”